Resource Logo
CDC HIV/AIDS/Viral Hepatitis/STD/TB Prevention News Update

GLOBAL: Bristol Adds Medicine to Patent Pool for AIDS Drugs




 

Reuters (12.12.2013)

Reuters recently reported that an agreement announced on December 12 by the UN-supported Medicines Patent Pool detailing Bristol-Myers Squibb’s sharing of intellectual property rights is the first to cover an HIV drug meant for use if patients develop resistance to initial treatments. The licensing agreement will allow generic drug firms around the world to manufacture more affordable versions of atazanavir, which Bristol sells under the brand name Reyataz. The move will make such second-line treatments more widely available in poorer countries. The World Health Organization estimates that more than 1 million individuals will be on these treatments by 2016.



 


Copyright © 2013 -CDC Prevention News Update, Publisher. All rights reserved to Information, Inc., Bethesda, MD. The CDC National Center for HIV, STD and TB Prevention provides the following information as a public service only. Providing synopses of key scientific articles and lay media reports on HIV/AIDS, other sexually transmitted diseases and tuberculosis does not constitute CDC endorsement. This daily update also includes information from CDC and other government agencies, such as background on Morbidity and Mortality Weekly Report (MMWR) articles, fact sheets, press releases and announcements. Reproduction of this text is encouraged; however, copies may not be sold, and the CDC HIV/STD/TB Prevention News Update should be cited as the source of the information. Contact the sources of the articles abstracted below for full texts of the articles.



Information in this article was accurate in December 13, 2013. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.